<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Boers, P.H.M.</title>
    <link>http://repub.eur.nl/res/aut/6182/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Characterization of recombinant influenza A virus as a vector for HIV-1 p17Gag (Article)</title>
      <link>http://repub.eur.nl/res/pub/24524/</link>
      <pubDate>2009-09-25T00:00:00Z</pubDate>
      <description>We have generated a recombinant influenza A virus with the HIV-1 p17Gag(rFlu-p17) gene inserted into the influenza virus neuraminidase (NA) gene. Expression of HIV-1 p17 protein was detected by conventional Western blot analysis and also by liquid chromatography/tandem mass spectrometry (LC-MS/MS) analysis of rFlu-p17 infected cells. The latter method does not depend on protein-specific antibody preparations and proved to be a powerful tool to detect proteins of interest. Next, antigen presentation of p17 expressed after infection of antigen-presenting cells was determined. Cloned p17-specific CD8+ T-cells were co-cultured with rFlu-p17 infected B-cells and produced IFN-γ upon stimulation. Furthermore, we showed that immunization with rFlu-p17 elicited a humoral immune response in mice. This study shows that replication-deficient rFlu-p17 is antigenic in vitro and immunogenic in vivo and warrants further development as a candidate vaccine vector. </description>
    </item> <item>
      <title>CCR5-restricted HIV type 2 variants from long-term aviremic individuals are less sensitive to inhibition by β-chemokines than low pathogenic HIV type 1 variants (Article)</title>
      <link>http://repub.eur.nl/res/pub/33112/</link>
      <pubDate>2008-03-01T00:00:00Z</pubDate>
      <description>Many HIV-2-infected individuals maintain low, often undetectable, viral loads for prolonged periods. Virus and/or host factors that contribute to this high level of virus control are largely unknown. Previously we demonstrated that HIV-2 variants from long-term aviremic individuals have relatively low replication kinetics in vitro in comparison to HIV-1 variants. We hypothesized that the relatively low replication rates of HIV-2 in vitro as well as the high level of virus control in vivo might be explained by HIV-2 replication being more sensitive to inhibitory host factors like β-chemokines or other CD8+T cell-derived factors than HIV-1 replication. To test this we determined the effect of exogenously added β-chemokines and healthy donor CD8+T cells on the in vitro virus production of HIV-2 and HIV-1 variants from long-term nonprogressors (LTNPs). Contrary to expectations, HIV-2 replication was inhibited less efficiently by RANTES and MIP-1α than HIV-1 replication. CD8+T cells from 8 of 12 healthy donors reduced HIV replication minimally 2-fold. Interestingly, cells from five of these donors inhibited HIV-1 but hardly affected HIV-2 replication, while the reverse was observed for cells from one donor. For HIV-1, but not HIV-2, the magnitude of the antiviral effect of CD8+T cells correlated with their effect on RANTES levels in culture supernatants. Our findings indicate that RANTES is a more important factor of CD8+T cell-associated anti-HIV-1 activity than it is of HIV-2 activity and that the benign clinical course of HIV-2 infection is not due to enhanced β-chemokine sensitivity of HIV-2 variants. </description>
    </item> <item>
      <title>CCR5, GPR15, and CXCR6 are major coreceptors of human immunodeficiency virus type 2 variants isolated from individuals with and without plasma viremia. (Article)</title>
      <link>http://repub.eur.nl/res/pub/13642/</link>
      <pubDate>2005-02-01T00:00:00Z</pubDate>
      <description>Human immunodeficiency virus type 2 (HIV-2) is generally considered capable of using a broad range of coreceptors. Since HIV-2 variants from individuals with nonprogressive infection were not studied previously, the possibility that broad coreceptor usage is a property of variants associated with progressive infection could not be excluded. To test this, we determined the coreceptor usage of 43 HIV-2 variants isolated from six long-term-infected individuals with undetectable plasma viremia. Using GHOST indicator cells, we showed for the first time that the only coreceptors efficiently used by low-pathogenic HIV-2 variants are CCR5, GPR15 (BOB), and CXCR6 (BONZO). Surprisingly, control HIV-2 variants (n = 45) isolated from seven viremic individuals also mainly used these three coreceptors, whereas use of CCR1, CCR2b, or CCR3 was rare. Nearly a quarter of all HIV-2 variants tested could infect the parental GHOST cells, which could be partially explained by CXCR4 usage. Use of CXCR4 was observed only for HIV-2 variants from viremic individuals. Thirty-eight variants from aviremic and viremic HIV-2-infected individuals were additionally tested in U87 cells. All except one were capable of infecting the parental U87 cells, often with high efficiency. When virus production in parental cells was regarded as background in the coreceptor-transduced cell lines, the results in U87 cells were largely in agreement with the findings in GHOST cells. HIV-2 isolates from aviremic individuals commonly use as coreceptors CCR5, GPR15, and CXCR6, as well as an unidentified receptor expressed by U87 cells. Broad coreceptor usage, therefore, does not appear to be associated with pathogenicity of HIV-2.</description>
    </item> <item>
      <title>HIV-2-Infected Individuals With Undetectable Plasma Viremia Carry Replication-Competent Virus in Peripheral Blood Lymphocytes (Article)</title>
      <link>http://repub.eur.nl/res/pub/3955/</link>
      <pubDate>2004-07-01T00:00:00Z</pubDate>
      <description>Using an optimized HIV co-culture protocol it was possible to isolate infectious HIV-2 variants from 6 HIV-2-infected individuals who had undetectable plasma viremia and maintained high CD4+ T-cell numbers for prolonged periods. This shows for the first time that HIV-2-infected individuals with no demonstrable in vivo virus production carry replication-competent virus in peripheral blood mononuclear cells (PBMCs). The frequency of PBMCs with infectious virus was low, ranging from 0.01–0.9 infectious units per million (IUPM) CD4+ T cells with a median value of 0.2 IUPM. In comparison, viremic HIV-2-infected individuals had a 2-log higher median infectious load (36 IUPM, range 1–673; P = 0.003). HIV-2 infectious load correlated with CD4 counts (rs = -0.88, P &lt; 0.0001). The low infectious load in aviremic HIV-2-infected persons is reminiscent of what has been observed for HIV-1 infection controlled by highly active antiretroviral therapy.</description>
    </item> <item>
      <title>Construction and characterisation of infectious recombinant HIV-1 clones containing CTL epitopes from structural proteins in Nef. (Article)</title>
      <link>http://repub.eur.nl/res/pub/3831/</link>
      <pubDate>2002-01-01T00:00:00Z</pubDate>
      <description>In this study the construction is described of HIV-1 molecular clones in which CTL epitopes from RT or Env late proteins were inserted into the Nef early protein. The ectopic epitopes were efficiently processed from the recombinant Nef proteins, were recognized by their cognate CTL in cytolytic assays, and did not perturb virus replication or viral protein expression in vitro. These recombinant viruses will therefore be an important tool in studying the effect of distinct epitope expression kinetics on the efficiency of CTL-mediated suppression of HIV-1 replication.</description>
    </item> <item>
      <title>Antibody-mediated enhancement of human immunodeficiency virus type 1 infectivity is determined by the structure of gp120 and depends on modulation of the gp120-CCR5 interaction (Article)</title>
      <link>http://repub.eur.nl/res/pub/9859/</link>
      <pubDate>2002-01-01T00:00:00Z</pubDate>
      <description>In this study, we characterized the viral determinants of coreceptor usage in relation to susceptibility to antibody-mediated neutralization or enhancement of infectivity by using chimeras of three highly related human immunodeficiency virus type 1 (HIV-1) isolates of different phenotypes. We found that the V3 region was the main determinant of antibody-mediated enhancement and coreceptor specificity but that the overall structure of gp120 was also important for these properties. Constructs susceptible to antibody-mediated enhancement preferentially use CCR5 as a coreceptor, in contrast to constructs that were neutralized or not affected. Using monoclonal antibodies directed against CD4 or CCR5, we were able to show that antibody-mediated enhancement was CD4 dependent. Altogether, our results suggest that the modulation of the interaction of gp120 with CCR5 is the mechanism underlying antibody-mediated enhancement of HIV-1 infectivity.</description>
    </item> <item>
      <title>Macrophage tropism of human immunodeficiency virus type 1 facilitates in vivo escape from cytotoxic T-lymphocyte pressure. (Article)</title>
      <link>http://repub.eur.nl/res/pub/12918/</link>
      <pubDate>2001-03-13T00:00:00Z</pubDate>
      <description>Early after seroconversion, macrophage-tropic human immunodeficiency virus type 1 (HIV-1) variants are predominantly found, even when a mixture of macrophage-tropic and non-macrophage-tropic variants was transmitted. For virus contracted by sexual transmission, this is presently explained by selection at the port of entry, where macrophages are infected and T cells are relatively rare. Here we explore an additional mechanism to explain the selection of macrophage-tropic variants in cases where the mucosa is bypassed during transmission, such as blood transfusion, needle-stick accidents, or intravenous drug abuse. With molecularly cloned primary isolates of HIV-1 in irradiated mice that had been reconstituted with a high dose of human peripheral blood mononuclear cells, we found that a macrophage-tropic HIV-1 clone escaped more efficiently from specific cytotoxic T-lymphocyte (CTL) pressure than its non-macrophage-tropic counterpart. We propose that CTLs favor the selective outgrowth of macrophage-tropic HIV-1 variants because infected macrophages are less susceptible to CTL activity than infected T cells.</description>
    </item> <item>
      <title>Broadening of coreceptor usage by human immunodeficiency virus type 2 does not correlate with increased pathogenicity in an in vivo model. (Article)</title>
      <link>http://repub.eur.nl/res/pub/3710/</link>
      <pubDate>2000-01-01T00:00:00Z</pubDate>
      <description>The pathogenic properties of four primary human immunodeficiency virus type 2 (HIV-2) isolates and two primary HIV-2 biological clones were studied in an in vivo human-to-mouse chimeric model. The cell-associated viral load and the ability to reduce the severity of the induced graft-versus-host disease symptoms, the CD4/CD8 ratio and the level of repopulation of the mouse tissues by the graft, were determined. All HIV-2 strains, irrespective of their in vitro biological phenotype, replicated to high titres and significantly reduced graft-versus-host disease symptoms as well as the CD4/CD8 ratios. Reduction of graft repopulation caused by infection with the respective HIV-2 strains showed that the in vitro replication rate, syncytium-inducing capacity and ability to infect human macrophages did influence the in vivo pathogenic potential whereas broadening of coreceptor usage did not.</description>
    </item> <item>
      <title>Decline of simian immunodeficiency virus (SIV)-specific cytotoxic T lymphocytes in the peripheral blood of long-term nonprogressing macaques infected with SIVmac32H-J5. (Article)</title>
      <link>http://repub.eur.nl/res/pub/3695/</link>
      <pubDate>1999-12-01T00:00:00Z</pubDate>
      <description>The evolution of simian immunodeficiency virus (SIV)–specific cytotoxic T lymphocyte precursors (CTLps) and their relationship with virus replication were studied in SIV‐infected macaques. After primary viremia, 3 of 8 macaques lost culturable virus and polymerase chain reaction–detectable provirus in peripheral blood. Although proviral DNA persisted in the spleen and lymph nodes, virus loads were below or barely above detection levels. Throughout the study, the 3 macaques remained asymptomatic, with stable CD4+ cell counts. These findings were associated with the detection of CTLps directed against both structural and regulatory SIV proteins. The response peaked during the first 7 months of infection but waned subsequently. CTLps increased after rechallenge of 1 macaque, suggesting that limited antigenic stimulation contributed to their disappearance from circulation. Transient viremia with increasing CTLp frequencies and antibody titers also suggested at least partial susceptibility to reinfection. These findings bear implications for vaccination strategies aimed at inducing protective CTLs against lentiviruses.</description>
    </item> <item>
      <title>Coreceptor usage of human immunodeficiency virus type 2 primary isolates and biological clones is broad and does not correlate with their syncytium-inducing capacities (Article)</title>
      <link>http://repub.eur.nl/res/pub/8838/</link>
      <pubDate>1998-01-01T00:00:00Z</pubDate>
      <description>Entry of human immunodeficiency virus type 1 (HIV-1) into target cells is
      mediated by binding of the surface envelope glycoprotein to the CD4
      molecule. Interaction of the resulting CD4-glycoprotein complex with
      alpha- or beta-chemokine receptors, depending on the biological phenotype
      of the virus, then initiates the fusion process. Here, we show that
      primary HIV-2 isolates and biological clones, in contrast to those of
      HIV-1, may use a broad range of coreceptors, including CCR-1, CCR-3,
      CCR-5, and CXCR-4. The syncytium-inducing capacity of these viruses did
      not correlate with the ability to infect via CXCR-4 or any other
      coreceptor. One cell-free passage of the intermediate isolates in
      mitogen-stimulated, CD8+ cell-depleted peripheral blood mononuclear cells
      resulted in the outgrowth of variants with CCR-5 only, whereas the
      coreceptor usage of late and early isolates did not change. Since HIV-2 is
      less pathogenic in vivo than HIV-1, these data suggest that HIV
      pathogenicity in vivo is not directly related to the spectrum of
      coreceptors used in in vitro systems.</description>
    </item> <item>
      <title>Kinetics of antiviral activity by human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL) and rapid selection of CTL escape virus in vitro (Article)</title>
      <link>http://repub.eur.nl/res/pub/8857/</link>
      <pubDate>1998-01-01T00:00:00Z</pubDate>
      <description>The antiviral activity of a CD8(+) cytotoxic T-lymphocyte (CTL) clone
      (TCC108) directed against a newly identified HLA-B14-restricted epitope,
      human immunodeficiency virus type 1 (HIV-1) Rev(67-75) SAEPVPLQL, was
      analyzed with respect to its kinetics of target cell lysis and inhibition
      of HIV-1 production. Addition of TCC108 cells or CD8(+) reverse
      transcriptase-specific CTLs to HLA-matched CD4(+) T cells at different
      times after infection with HIV-1 IIIB showed that infected cells became
      susceptible to CTL-mediated lysis before peak virus production but after
      the onset of progeny virus release. When either of these CTLs were added
      to part of the infected cells immediately after infection, p55 expression
      and virus production were significantly suppressed. These data support a
      model in which CTLs, apart from exerting cytolytic activity which may
      prevent continued virus release, can interfere with viral protein
      expression during the eclipse phase via noncytolytic mechanisms.
      TCC108-mediated inhibition of virus replication in peripheral blood
      mononuclear cells caused rapid selection of a virus with a mutation
      (69E--&gt;K) in the Rev(67-75) CTL epitope which abolished recognition by
      TCC108 cells. Taken together, these data suggest that both cytolytic and
      noncytolytic antiviral mechanisms of CTLs can be specifically targeted to
      HIV-1-infected cells.</description>
    </item> <item>
      <title>Coreceptor usage of human immunodeficiency virus type 2 primary isolates and biological clones is broad and does not correlate with their syncytium-inducing capacities. (Article)</title>
      <link>http://repub.eur.nl/res/pub/3651/</link>
      <pubDate>1998-01-01T00:00:00Z</pubDate>
      <description>Entry of human immunodeficiency virus type 1 (HIV-1) into target cells is mediated by binding of the surface envelope glycoprotein to the CD4 molecule. Interaction of the resulting CD4-glycoprotein complex with alpha- or beta-chemokine receptors, depending on the biological phenotype of the virus, then initiates the fusion process. Here, we show that primary HIV-2 isolates and biological clones, in contrast to those of HIV-1, may use a broad range of coreceptors, including CCR-1, CCR-3, CCR-5, and CXCR-4. The syncytium-inducing capacity of these viruses did not correlate with the ability to infect via CXCR-4 or any other coreceptor. One cell-free passage of the intermediate isolates in mitogen-stimulated, CD8+ cell-depleted peripheral blood mononuclear cells resulted in the outgrowth of variants with CCR-5 only, whereas the coreceptor usage of late and early isolates did not change. Since HIV-2 is less pathogenic in vivo than HIV-1, these data suggest that HIV pathogenicity in vivo is not directly related to the spectrum of coreceptors used in in vitro systems.</description>
    </item> <item>
      <title>Impact of natural sequence variation in the V2 region of the envelope protein of human immunodeficiency virus type 1 on syncytium induction: A mutational analysis. (Article)</title>
      <link>http://repub.eur.nl/res/pub/3544/</link>
      <pubDate>1995-01-01T00:00:00Z</pubDate>
      <description>Several studies have demonstrated a functional role for the V1-V2 region of the human immunodeficiency virus type 1 (HIV-1) envelope surface glycoprotein gp120 in the membrane fusion processes underlying viral entry and syncytium induction. In a study with chimeric primary envelope genes, we have previously demonstrated that the exchange of V2 regions was sufficient to transfer syncytium-inducing capacity to a non-syncytium-inducing envelope protein. The exchanged V2 regions, comprising a number of variable amino acids, conferred changes to both the predicted secondary structure and to the net positive charge of the V2 loops. In a syncytium-forming assay based on transient envelope protein expression in CD4+ SupT1 cells, we have extended this observation by mutating the variable positions of the V2 region to determine the relative contribution of individual amino acids to syncytium formation. It can be shown that simultaneous mutation of multiple amino acids is needed to interfere with the V2 region-determined syncytium-inducing phenotype. Single amino acid changes either influencing charge of predicted secondary structure of the V2 loop proved to be insufficient to abolish V2 region-controlled syncytium formation. This robust V2 organization may allow the virus to accumulate mutations, while retaining its biological phenotype.</description>
    </item>
  </channel>
</rss>